Marilynn Larkin June 02, 2024 Nearly 2 years after their final infusion with the IGF-IR inhibitor teprotumumab (Tepezza), 82% of patients with thyroid eye disease did not need further treatment for their symptoms, revealed research presented today at ENDO 2024 and published in Thyroid. “Thyroid eye disease is a lifelong autoimmune disease that can worsen...